Waters will join several venture investors including, Floodgate Capital, First Round Capital, Underscore VC, Founder Collective, and Y Combinator, to invest in TetraScience’s $8-million series A round of financing.
TetraScience, a Boston, MA-based cloud technology company for life sciences R&D, announced on Oct. 31, 2019 it obtained a strategic investment from Waters, a specialty measurement company located in Milford, MA.
Waters will join several venture investors including, Floodgate Capital, First Round Capital, Underscore VC, Founder Collective, and Y Combinator, to invest in TetraScience’s $8-million series A round of financing, according to a press release. TetraScience will use the funding to develop its commercial team and its list of global customers and partners.
"We are honored by this vote of confidence from a renowned industry leader," said Siping (Spin) Wang, co-founder and CEO of TetraScience, in the press release. "Waters Corporation brings to the table [more than] 60 years of experience in high value analytical technologies, scientific expertise, and a global footprint. We look forward to working together to transform the future of R&D."
"We believe that dynamic, young companies like TetraScience have an enabling role to play in advancing the way the scientific community collects, shares, and analyzes R&D data," added Alan Millar, senior director of Corporate Development for Waters, in the press release. "Waters is excited to support TetraScience via this investment."
Source: TetraScience
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.